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Cervical cancer is the fourth most frequent cancer in women worldwide (1). Early stage disease is treated with surgery or chemoradiotherapy and has a good prog-nosis. However, around 30% of all patients treated for cervical carcinoma develop 
progressive or recurrent tumors (2).
Recurrent cervical cancer is defined as local tumor regrowth or the development of dis-
tant organ/lymph node metastases at least six months after regression of the initial lesion. 
Approximately two-thirds of recurrences appear within the first two years following initial 
treatment, with 90% recurring by five years post-treatment (3). Risk factors for recurrence 
include histopathologic features, depth of tumor invasion, and nodal status (4).
Pelvic recurrence can be located centrally (cervix, uterus, vagina, parametria, ovaries, 
bladder, or rectum) or in the pelvic sidewalls. Extrapelvic recurrence most commonly in-
volves the para-aortic lymph nodes, lungs, liver, or bone (4–6).
Treatment of recurrent cancer depends on the primary treatment approach, location, and 
extension. Patients with locally recurrent disease can be offered salvage treatments with 
curative potential (chemoradiotherapy, if not given previously, or pelvic exenteration in pa-
tients who already received chemoradiotherapy). Distant metastases, however, are nearly 
always incurable (3).
In patients who successfully completed primary treatment, surveillance has been advocat-
ed  to detect the residual or recurrent disease at curable stages (7). The use of imaging studies 
such as magnetic resonance imaging (MRI) is indicated on the basis of clinical suspicion (8).
T2-weighted (T2W) imaging is the reference sequence for cervical cancer staging (9). Re-
current tumors are known to show high signal intensity on T2W MRI, contrasting with the low 
signal intensity of the cervical stroma. However, some benign conditions such as necrosis, 
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PURPOSE 
We aimed to evaluate the added value of diffusion-weighted imaging (DWI) to standard magnetic 
resonance imaging (MRI) for detecting post-treatment cervical cancer recurrence. The detection 
accuracy of T2-weighted (T2W) images was compared with that of T2W MRI combined with either 
dynamic contrast-enhanced (DCE) MRI or DWI.
METHODS
Thirty-eight women with clinically suspected uterine cervical cancer recurrence more than six 
months after treatment completion were examined with 1.5 Tesla MRI including T2W, DCE, and 
DWI sequences. Disease was confirmed histologically and correlated with MRI findings. The diag-
nostic performance of T2W imaging and its combination with either DCE or DWI were analyzed. 
Sensitivity, positive predictive value, and accuracy were calculated.
RESULTS
Thirty-six women had histologically proven recurrence. The accuracy for recurrence detection was 
80% with T2W/DCE MRI and 92.1% with T2W/DWI. The addition of DCE sequences did not signifi-
cantly improve the diagnostic ability of T2W imaging, and this sequence combination misclassified 
two patients as falsely positive and seven as falsely negative. The T2W/DWI combination revealed 
a positive predictive value of 100% and only three false negatives.
CONCLUSION
The addition of DWI to T2W sequences considerably improved the diagnostic ability of MRI. Our 
results support the inclusion of DWI in the initial MRI protocol for the detection of cervical cancer 
recurrence, leaving DCE sequences as an option for uncertain cases.
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inflammation, and edema may also increase 
signal intensity on T2W images, representing 
a potential challenge to the radiologist, par-
ticularly after radiotherapy (10–13). 
Moreover, post-treatment changes can 
result in areas of fibrosis that are also dif-
ficult to differentiate from recurrence (14). 
MRI has proven to be superior to computed 
tomography (CT) in distinguishing fibrosis 
and scarring from active disease, but imag-
ing findings are sometimes indeterminate, 
complicating the evaluation of recurrent 
disease (3).
In recent years, the functional MRI 
techniques such as dynamic multiphase 
contrast-enhanced (DCE) MRI and dif-
fusion-weighted imaging (DWI) have 
emerged as fundamental tools in female 
pelvic imaging evaluation (15). Although 
DCE was shown to be more accurate than 
T2W alone for tumor recurrence identifica-
tion, the use of both sequences is recom-
mended (10).
Recently, DWI has been added to pelvic 
MRI protocols to increase diagnostic accu-
racy in tumor staging. This technique is a 
functional tool that relies on tissue water dis-
placement to create a contrasted image. For 
correct evaluation and avoidance of pitfalls, 
the generated images must be interpreted 
alongside anatomical sequences. The appar-
ent diffusion coefficient (ADC) map is also 
needed to reduce image misinterpretation, 
for example due to the T2 shine-through 
effect (15). In highly cellular tissues, water 
movement is restricted and such lesions ap-
pear bright at high b-values (1000 s/mm2) 
and have low ADC value, appearing dark gray 
on ADC maps in contrast to areas of freely 
moving water such as urine in the bladder 
(14). Some recent studies have suggested 
that DWI and ADC maps can be potentially 
useful in oncologic follow-up (14, 16).
The purpose of this study was to compare 
the accuracy of T2W/DWI with that of con-
ventional anatomical sequences alone and 
T2W/DCE imaging sequences in the evalua-
tion of recurrent disease in patients treated 
for uterine cervical carcinoma.
   Methods 
Patient selection
This is a retrospective, institutional re-
view board-approved single-center study. 
From May 2013 until July 2014, a total of 
38 female patients (median age, 58 years; 
range, 28–85 years) with clinically suspect-
ed cervical cancer recurrence underwent 
standard pelvic examinations and pelvic 
MRI. All patients included in the study were 
women who had undergone treatment for 
cervical cancer, had completed their ther-
apeutic regimens at least six months prior 
to study entry, and had clinical suspicion of 
tumoral recurrence.
As primary treatment, nine patients un-
derwent hysterectomy, one received radio-
therapy only, and the remaining 28 patients 
received combined radiochemotherapy. 
Clinical suspicion of recurrence was as-
sociated with particular symptoms such as 
pelvic pain (n=25), metrorrhagia (n=2), he-
maturia (n=1), and fecaluria (n=1). The oth-
er nine patients had macroscopic lesions 
detected during gynecologic follow-up ex-
aminations. 
Thirty-four women underwent biopsy of 
the suspicious lesion and four women un-
derwent surgery for lesion excision.
MRI protocol 
All MRI studies were performed on a 1.5 
Tesla body scanner unit (Philips Intera Pul-
sar) with a pelvic phased-array coil (Syner-
gy). Peristalsis was suppressed with 40 mg 
of N-butylscopolamine bromide. Superior 
and anterior saturation bands were used.
The pelvis was examined using axial tur-
bo spin-echo T1-weighted sequence (TR/
TE, 400 ms/10 ms; matrix size, 512×512; 
slice thickness, 4 mm; gap, 0.4 mm) and a 
set of spin-echo T2-weighted sequence (TR/
TE, 5000 ms/102 ms; matrix size, 512×512; 
number of excitations, 2; slice thickness, 4 
mm; gap, 0.4 mm) in the sagittal and axial 
planes. In women who did not undergo 
surgery as primary treatment, an addition-
al T2W (slice thickness, 5 mm; gap, 0.5 mm) 
axial oblique (perpendicular to the cervical 
canal) sequence was performed. An axial 
spin-echo T2W sequence (slice thickness, 6 
mm; gap, 1 mm) of the abdomen extending 
from the pelvic brim to the left renal vein 
was also performed. 
Fat-suppressed T1 3D gradient echo ac-
quisitions of the pelvis (frequency-selective 
suppression SPAIR—Spectral Attenuated 
Inversion Recovery) were obtained in the 
sagittal or axial plane (accordingly to the 
individual preferences of the performing 
radiologist) after a bolus injection of gad-
oteric acid (Dotarem, Laboratoire Guerbet) 
at a dose of 0.1 mmol/kg of body weight 
followed by a rapid infusion of normal sa-
line solution (10 mL). Injection started after 
the first acquisition, and scanning was con-
ducted at 30, 60, 90, 120, and 150 s after the 
injection. We also obtained a late (taken at 
5 min) T1W spectral presaturation inversion 
recovery (SPIR) sequence in the axial plane.
In three patients, contrast-enhanced 
imaging was impossible due to impaired 
renal function (glomerular filtration rate 
<30 mL/min).
DWI was performed for both the abdo-
men and pelvis using single-shot echo-pla-
nar imaging and the array spatial sensitivity 
encoding technique (SENSE) (TR/TE, 3100 
ms/53 ms; matrix size, 256×256; number of 
excitations, 3; slice thickness, 4 mm; gap, 1 
mm; R factor, 2; flip angle, 90º) in the axial 
plane with a b-value of 0, 600, and 1000 s/
mm2. The image software automatically 
generated ADC maps. 
Image analysis
Two radiologists (with 4 and 19 years of 
experience in interpreting pelvic MRI) per-
formed a consensus interpretation of all 
images while blinded to the histopathology 
reports to determine whether lesions were 
recognizable on T2W and DCE imaging, and 
also on DWI (with b=1000). 
Four separate sets of images were ana-
lyzed: anatomical images only (T2W), DCE 
sequences, T2W and DCE sequences (T2W/
DCE), and T2W and DWI sequences (T2W/
DWI). To minimize any recall bias, the ex-
ams were sorted randomly and a two-week 
interval was present was present between 
interpretation sessions. T1-weighted imag-
es were also analyzed in each set to exclude 
potential pitfalls such as hemorrhage.
DWI sequences were not evaluated alone 
because of the lack of anatomical referenc-
es. In the combined sets of sequences, DCE 
Main points
• Recurrent cervical cancer is defined as tumor re-
growth or the development of metastases, at least 
six months after regression of the initial lesion.
• Recurrent tumors are known to show high signal 
intensity on T2W imaging, but also necrosis, 
inflammation and edema. Post-treatment changes 
can result in areas of fibrosis that are also difficult to 
differentiate from recurrence.
• The addition of DCE MRI improves T2W imaging 
sensitivity, however, sometimes it is not possible 
to administer contrast, e.g., due to kidney function 
impairment. 
• The rates of tumoral detection were higher with 
the combination of T2W/DWI sequences. 
• The initial MRI protocol for the detection of cervical 
cancer recurrence could consist of the combination of 
T2W imaging and DWI, leaving DCE MRI as an option.
and DWI sequences were synchronized 
with T2W images for better lesion localiza-
tion and the avoidance of pitfalls.
DWI (with b=1000) was analyzed qual-
itatively according to the signal intensity 
of uterine cervical cancer, as determined 
by visually comparing the signal intensity 
with the myometrium signal. ADC maps 
were also analyzed qualitatively. T2 shine-
through artifacts (high signal on DWI with 
normal or high-signal ADC) were not con-
sidered as true restricted diffusion.
For DCE MRI, all acquisitions were an-
alyzed together, and the early enhance-
ments (30–90 s) of any abnormal structure, 
as well as isolated enhancing areas, were 
registered. Each observer individually re-
corded the presence and location of lesions 
in each set of images (T2W, DCE, and DWI), 
assigning each as: (a) “suspicious for recur-
rent disease” (in patients exhibiting lesions 
with a high signal intensity on T2W imaging 
compared with muscle, early contrast up-
take on DCE sequence, or bright and dark 
areas on DWI and ADC maps); (b) “unappar-
ent disease” (when no lesion was identifi-
able); or (c) “ill-defined/equivocal disease” 
(when there was only a slight signal eleva-
tion in an ill-defined area on T2W image, 
delayed contrast uptake on DCE image, or 
only a discrete signal elevation on b=1000 
or a discrete hyposignal on the ADC map). 
In the combination sets, when at least 
one technique was suspicious for malig-
nancy the global result was considered sus-
picious for recurrent disease. 
Histopathology examination
All biopsy results were reviewed by geni-
tourinary pathologists blinded to the imag-
ing findings. 
Statistical analysis 
MRI and histopathology results were cor-
related for each patient. A general descrip-
tive analysis was performed for each vari-
able. Using the histology results as a gold 
standard, we calculated sensitivity, positive 
predictive value, and accuracy for T2W and 
DCE imaging alone and for sequences com-
binations (T2W/DCE and T2W/DWI). The ac-
curacy of the T2W sequence was compared 
with that of the DCE sequence and the se-
quence combinations (T2W/DCE and T2W/
DWI) using a nonparametric test (McNemar 
two-tailed test). Then, a similar statistical 
comparison was made between the two se-
quence combinations. A P ≤ 0.05 was con-
sidered statistically significant. All statistical 
analyses were performed using SPSS Statis-
tics for Windows, Version 17.0 (SPSS Inc.).
   Results  
Of the 38 suspicious lesions on MRI, 36 
were proven to be recurrent disease on his-
topathologic examination and two showed 
no signs of neoplastic disease. The sites of 
recurrent disease were the cervix (n=13), 
vaginal vault (n=9), vaginal wall (n=4), uter-
ine body (n=1), posterior bladder wall (n=1), 
and retroperitoneal lymph nodes (n=10).
Patient demographics, histology of the 
primary treated tumor, FIGO stage at di-
agnosis, and histology and location of the 
suspicious lesion are summarized in Table 1.
Table 2 depicts the concordance be-
tween the MRI analyses and the histology 
results. For each image set, the sensitivity, 
positive predictive value, and accuracy for 
lesion detection are also presented.
T2W sequences correctly depicted 28 tu-
moral recurrences via hyperintensity criteria. 
Four lesions were misclassified as “unappar-
ent disease” because they were isointense/
slightly hypointense and four were misclas-
sified as “ill-defined/equivocal disease” be-
cause there was only a slight signal elevation 
that was difficult to differentiate from the 
normal myometrium (Fig. 1). Two patients 
were erroneously classified as having “recur-
rent disease” due to focal cervical (Fig. 2) and 
retroperitoneal lymph node hyperintensity. 
Only 35 patients underwent DCE se-
quence since a contrast-enhanced study was 
impossible in three patients due to kidney 
function impairment. Considering all DCE 
acquisitions for each patient, 28 malignant 
lesions were identified. Of these, 27 lesions 
had also been depicted on T2W imaging. The 
last lesion was only defined after contrast ad-
ministration. Four malignant lesions showed 
no significant early contrast uptake and 
were classified as “unapparent disease,” and 
another with just discrete contrast uptake 
was considered equivocal. Two lesions with 
early contrast enhancement were benign on 
histopathologic work-up (false positive find-
ings). There was no statistically significant 
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Table 1. Patient characteristics 
Number of patients 38
Histology of primary tumor, n (%)
 Squamous cell carcinoma  34 (89.5)
 Adenocarcinoma 4 (10.5)
FIGO stage at diagnosis, n ( %) 
 IA 1 (2.6)
 IB 2 (5.2)
 IIA  7 (18.4)
 IIB  23 (60.5)
 IIIA 1 (2.6)
 IIIB 4 (10.5)
Histology of suspicious lesion, n (%)
 Squamous cell carcinoma  34 (89.5)
 Adenocarcinoma 2 (5.25)
 Benign  2 (5.25)
Median age at recurrence diagnosis (years) 58
Location of the lesion suspicious of recurrence, n (%) 
 Cervix 13 (34.2)
 Vaginal vault 9 (23.7)
 Vaginal wall 4 (10.5)
 Uterine body 1 (2.6)
 Posterior bladder wall 1 (2.6)
 Retroperitoneal lymph nodes 10 (26.3)
FIGO, International Federation of Gynecology and Obstetrics. 
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difference between the accuracy of T2W and 
DCE imaging (P > 0.05).
The T2W/DCE imaging combination cor-
rectly classified 28 lesions as malignant. The 
addition of contrast allowed for the correct 
identification of one additional lesion in a 
patient with an enhancing focal area not 
seen on the morphologic (T2W) sequence. 
However, one patient with a suspicious le-
sion on T2W imaging could not be evaluat-
ed with DCE MRI (due to contraindications 
to contrast administration) and was there-
fore not included in the statistical analysis 
of this combination. Combined T2W/DCE 
imaging was unable to exclude malignancy 
in two women with clinical suspicion of re-
current disease (both complaining of pelvic 
pain) but only benign changes on patho-
logic analysis. There was no statistically sig-
nificant difference between the accuracies 
of T2W and T2W/DCE imaging (P > 0.05).
When evaluating the combined imaging 
findings of T2W/DWI, 33 of the recurrent tu-
mors were correctly identified (Fig. 3). 
The two disease-free women who were 
misclassified using the T2W/DCE sequences 
were correctly categorized as “unapparent 
disease” with this combination. Three le-
sions were unapparent (Fig. 4). There was 
no statistically significant difference in ac-
curacy between the T2W/DCE and T2W/
DWI combinations (P > 0.05). However, the 
difference in diagnostic accuracy between 
T2W imaging and T2W/DWI was statistically 
significant (P = 0.016). 
These results support the assumption 
that the rates of tumor recurrence detec-
tion are similar between a complete multi-
parametric MRI study (combination of mor-
phologic sequences with DCE and DWI) and 
a combination of T2W/DWI.
   Discussion  
In our study, the combination T2W/DWI 
had a positive predictive value of 100% and 
an accuracy of 92.1% for recurrent disease 
detection, while both T2W imaging alone 
and the combination T2W/DCE MRI regis-
tered values of 93.3% and 80%, respective-
ly. Also there were no false positive findings 
with T2W/DWI.
The identification of a recurrent tu-
mor has a major impact on the survival 
outcomes of patients treated for cervical 
cancer. Imaging is undertaken only in the 
presence of suspicious clinical symptoms. 
However, residual disease is difficult to eval-
uate and the accuracy of MRI depends on 
the time elapsed since the end of therapy, 
as local inflammatory or fibrotic phenom-
ena may hamper accurate diagnosis (7, 11, 
14, 17, 28).
Conventional MRI has a high sensitivity 
but low specificity for recurrent disease de-
tection. Thus, the added value provided by 
functional MRI is becoming increasingly im-
Figure 1. a–d. MRI in the axial plane of the pelvis denoting vaginal recurrence of endometrioid 
adenocarcinoma of the cervix (initial stage IIB) treated with chemoradiotherapy. On T2-weighted (a) and 
dynamic contrast-enhanced (DCE) (b) MRI sequences, no obvious lesion was identified. On diffusion-
weighted imaging (DWI) with b=1000 s/mm2 (c), the tumor is clearly defined with a hypersignal and low 
signal on the apparent diffusion coefficient (ADC) map (d).
c
a
d
b
Table 2. Performance of each MRI technique separately and in combination 
 T2W DCE T2W/DCE T2W/DWI
n 38 35 35 38
TP/correctly identified 28 (73.7) 28 (80) 28 (80) 33 (86.8)
FP/incorrectly identified 2 (5.3) 2 (5.7) 2 (5.7) 0 (0)
TN/correctly rejected 0 (0) 0 (0) 0 (0) 2 (5.3)
FN/incorrectly rejected 8 (21.0) 5 (14.3) 5 (14.3) 3 (7.9)
Unable to perform 0  3  3  0 
PPV, TP/(TP+FP) 93.3 93.3 93.3 100
Sensitivity, TP/(TP+FN) 77.8 84.8 84.8 91.7
Accuracy, (TP+TN)/total  73.6 80 80 92.1
P (comparison with T2W) - 1.000 1.000 0.016
Data are presented as n (%).
T2W, T2-weighed; DCE, dynamic contrast-enhanced; DWI, diffusion-weighted imaging; n, number of patients; TP, true 
positive; FP, false positive; TN, true negative; FN, false negative; PPV, positive predictive value.
portant in oncologic diagnosis, particularly 
in gynecologic cancers, where newer appli-
cations have been gaining ground (18, 19).
In DCE MRI, a dynamic image acquisition 
is performed after the administration of an 
intravenous bolus of gadolinium-based con-
trast agent. The paramagnetic contrast mol-
ecules lead to changes in local field strength 
and thus reflect the tumor microvascular net-
work (20). Typically, cervical tumors enhance 
avidly in the early dynamic phase compared 
with the slight enhancement of the cervical 
epithelium and stroma, which may allow 
for the distinction of recurrent tumors from 
radiation fibrosis (21). However, the use of 
gadolinium-based contrast media is limited 
in patients with kidney impairment (patients 
with glomerular filtration rates <30 mL/min, 
patients on dialysis, and patients with acute 
kidney insufficiency), as well as in cases of al-
lergy requiring medical treatment, pregnan-
cy, or patient refusal (22).
DWI is a noninvasive technique based on 
molecular diffusion that, combined with 
conventional T2W imaging, enables the as-
sessment of morphologic and physiologic 
changes in a single examination. It also al-
lows for a quantitative evaluation of ADC 
from images with different b-values (15, 23, 
24). DWI can provide excellent tissue con-
trast, making it an excellent choice in cases 
where contrast administration is not possi-
ble. Furthermore, the additional scanning 
time is relatively short.
Numerous studies have described the 
use of DWI for the diagnosis and staging 
of cervical cancer (3, 9, 14–16, 23, 25, 26). 
However, only few studies have analyzed 
the utility of DWI in assessing early tumor 
response to treatment (4, 17, 24, 27). To our 
knowledge, there are no published data on 
the use of DWI for cervical tumor recurrence 
detection and no studies have compared 
DCE MRI and DWI in this field. 
We recognize that pelvic DWI is an 
extremely motion-sensitive sequence 
plagued by artefacts related to arterial pul-
sation, bowel peristalsis, and susceptibility 
effects. However, advances in hardware 
and sequences have contributed to the 
minimization of these effects, increasing 
the use of DWI in pelvic pathology (26). It 
is also well known that high b-value imag-
es have low anatomical detail, but this can 
be overcome by fusing the images with 
anatomical sequences to optimize anatom-
ical correlation. These fused images can be 
displayed in inverted grey-scale or arbitrary 
color-coded scales (15).
In our study, T2W imaging alone could 
identify recurrent tumors with a sensitivi-
ty of 77.8%. Histopathology examinations 
of the false negative patients revealed 
squamous cell carcinoma cells involved by 
abundant fibrous tissue. This may justify the 
absence of a high signal on T2W imaging, 
especially considering that six of these pa-
tients have had chemoradiotherapy, which 
is known to decrease tumor signal intensity 
on MRI (28, 29).
These results are concordant with the 
work of Hricak et al. (12), who found that 
tumors with intense desmoplastic reactions 
demonstrate a low signal on T2W imaging. 
In addition, Kinkel et al. (10) found that the 
presence of both fibrosis and tumor cells in 
the same lesion could justify the lower sig-
nal intensity on T2W imaging, with a higher 
reported T2W imaging sensitivity (91.4%). 
However, this study included other gyne-
cologic cancers besides cervical cancer, 
which can explain this difference. On the 
other hand, all the false negative lesions in 
their study were from patients treated for 
cervical cancer, reflecting the difficulties in 
establishing this diagnosis. 
In this study, in cases where the morpho-
logic sequences failed to identify tumor re-
currence, DCE MRI could correctly identify 
only one additional lesion. This was in a pa-
tient treated with chemoradiotherapy who 
showed an early enhancing area in the vag-
inal wall that was ill-defined and difficult to 
depict on T2W imaging, probably due to 
the presence of radiation-induced fibrosis 
precluding higher signal intensity on T2W 
imaging.
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Figure 2. a–e. Pelvic MRI of a 42-year-old patient who underwent chemoradiotherapy for cervical cancer 
that ended one year ago (initial stage IIB). On sagittal (a) and axial (b) T2-weighted images an irregular 
cervical nodular lesion is identified with necrotic center and ill-defined intermediate signal on the 
periphery. On sagittal DCE MRI (c) an early heterogeneous peripheral enhancement is seen. On axial DWI 
with b=1000 s/mm2 (d) the lesion shows diffuse hyperintense signal, mainly due to central necrosis and 
there is no peripheral low signal on the correspondent ADC map (e) denoting T2 shine-through effect, 
without evidence of restricted diffusion. Histopathology examination revealed only inflammatory changes.
d
a
e
b
c
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Three patients could not undergo a con-
trast-enhanced study due to kidney impair-
ment (in one of these patients a tumoral 
lesion was readily identified on T2W imag-
ing) and five patients remained incorrectly 
diagnosed (false negative). This did not 
represent a significant difference in sensi-
tivity between these two sequences. Sala 
et al. (15) also concluded that DCE MRI was 
not necessary during staging, as it could 
not improve accuracy compared with T2W 
imaging alone, which increased our confi-
dence. In the Kinkel et al. study (10) based 
on subtraction DCE MRI, there was also no 
increment in sensitivity with contrast-en-
hanced studies compared with anatomical 
sequences only. However, tumor identifi-
cation accuracy was superior with contrast, 
with maximum tumor enhancement oc-
curring between 45 and 90 s after contrast 
administration (10). In our study, all patients 
with early enhancement (30–90 s) were his-
tologically proven. 
Among lesions that did not show early 
enhancement (false negative), two were 
recurrences in the vaginal vaults of hyster-
ectomized patients who received neoadju-
vant chemotherapy and three were cervical 
lesions in patients who completed chemo-
radiotherapy at least two years ago. On 
pathology, all these lesions revealed abun-
dant fibrous stroma with scant microscopic 
tumor foci. The former may be related to 
post-surgical fibrosis, whereas the latter 
may be due to post-radiotherapy vasculop-
athy, which affects the microvasculature of 
irradiated fields and thereby limits the early 
enhancing capacity of these lesions (12).
We found that the two false-positive 
findings on T2W imaging remained false 
positive after the addition of DCE MRI. Histo-
pathologic examination of these patients re-
vealed inflammatory changes, necrosis, and 
hyperemia in a cervical lesion of a patient 
who completed chemoradiotherapy one 
year ago and an enlarged retroperitoneal 
lymph node with inflammatory changes and 
increased vessel density in a patient who 
underwent hysterectomy 18 months prior. 
Engin (28) reviewed postirradiation changes 
in pelvic organs and found that sometimes 
the tumoral signal decrease typical of radia-
tion therapy may be delayed, and a high-sig-
nal-intensity stroma may persist longer (28). 
In the study by Hricak et al. (12), there was 
also nonspecific enhancement of the cervix 
after radiation therapy related to benign 
changes such as postirradiation fibrosis, in-
flammation, and necrosis. Furthermore, in 
another paper by Hawighorst et al. (13), the 
visual inspection of a lesion’s contrast en-
hancement alone was considered unhelpful 
in establishing a malignancy diagnosis be-
cause of nonspecific tissue changes that can 
show similar enhancement. In contrast with 
these works, Kinkel el al. (10) found that DCE 
MRI is helpful in improving the specificity 
and accuracy of tumor recurrence detection. 
They also proved that in the first five months 
after radiation therapy, induced inflammato-
ry changes are known to be responsible for 
early enhancement that mimics recurrence. 
We believe that this effect may be prolonged 
in some patients. 
In our study, we observed that the combi-
nation of T2W imaging and DWI could pre-
dict tumor recurrence with a higher sensi-
tivity than the combination of T2W and DCE 
MRI (91.7% vs. 84.8%). The addition of DWI 
to T2W imaging allowed five patients to be 
reclassified as having a recurrent tumor.
On the other hand, the two false-positive 
patients with bright lesions on T2W imag-
ing and early enhancement after contrast 
administration did not show water restric-
tion on DWI, denoting the absence of high 
cellularity of these benign changes (Fig. 3). 
These results are in concordance with those 
of Chen et al. (26), who found that patients 
without disease after treatment showed no 
residual hyperintense lesions in the cervical 
areas on DWI. 
The three cases that remained falsely 
negative on all sequences represented bi-
opsy-proven local recurrences of well-dif-
ferentiated squamous carcinoma that did 
Figure 3. a–f. Pelvic MRI of a 55-year-old patient who underwent chemoradiotherapy for cervical cancer (initial stage IIIB) with central recurrent disease after 
treatment. On axial T2-weighted image performed four years after treatment (a), no lesion was promptly identifiable, although DWI with b=1000 (b) showed a 
small focal area of hyperintensity on the right posterior bladder wall with a discrete hyposignal on the ADC map (c) that was not promptly considered relevant by 
the clinicians. After this examination, a targeted biopsy was performed confirming recurrence of cervical squamous cell carcinoma (this first evaluation was the 
one included in our study). The patient refused treatment for personal reasons and one year later, a hyperintense heterogeneous cervical mass with right posterior 
bladder invasion is readily visible on T2-weighted image (d) along with a high signal on DWI with b=1000 s/mm2 (e) and a low signal on the ADC map (f). 
d
a
e f
b c
not show marked restricted diffusion, prob-
ably due to their low cellularity (30).
Globally, in this study, the accuracy was 
73.6% for T2W imaging, 80% for DCE MRI, 
80% for combined T2W/DCE MRI, and 
92.1% for combined T2W/DWI.
Our study had several limitations. First, 
our population was small and had a high 
prevalence of recurrence, which could lead 
to the overestimation of sensitivity and 
render the estimation of specificity im-
possible. Second, DWI was assessed only 
qualitatively by inspecting signal intensity, 
as there is no established ADC value that 
is diagnostic for neoplastic tissue (because 
imaging parameters change from center 
to center, making standardization almost 
impossible). Third, contrast could not be 
administered in three patients, thus the 
entire patient sample could not undergo 
evaluation with the T2W/DCE MRI combi-
nation. However, this is also a limitation 
in everyday practice, which reinforces the 
role of DWI as an alternative to contrasted 
studies in tumoral recurrence follow-up. 
Fourth, the patient group is not homoge-
neous with regard to therapeutic options 
that may have conditioned the appear-
ance of pelvic structures on follow-up MRI. 
This point warrants further studies with 
larger samples. Finally, there is inhomo-
geneity regarding recurrence site, but this 
actually represents the pattern of cervical 
cancer recurrence, which can have a local 
or regional distribution in the form of pel-
vic or para-aortic adenopathy (28).
In conclusion, although we recognize 
that our data are presented on the basis of 
preliminary observations that are sustained 
by histopathologic confirmation and a sig-
nificant difference on statistical analysis, 
we hypothesize that in follow-up study of 
patients treated for cervical cancer, contrast 
administration can be omitted from the ini-
tial protocol. We hereby support the notion 
that an initial follow-up protocol for treated 
cervical cancer can consist of a T2W/DWI 
combination, which can save both time and 
money. DCE MRI would only be performed 
if the radiologist remained uncertain re-
garding the diagnosis. 
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